Patents Examined by Alana Harris Dent
  • Methods for detecting an amount of complement factor B protein and carbohydrate antigen 19-9 protein, and methods for diagnosing and treating pancreatic cancer using the same
    Patent number: 10656154
    Abstract: The present application relates to a kit for diagnosing pancreatic cancer, a method for providing information for diagnosing pancreatic cancer using the kit, and a method for diagnosing pancreatic cancer using same, wherein the kit includes an antibody specifically binding to complement factor B protein and an antibody specifically binding to carbohydrate antigen 19-9 protein. According to the present application, it is possible to provide a marker for diagnosing pancreatic cancer having enhanced sensitivity and specificity.
    Type: Grant
    Filed: November 10, 2016
    Date of Patent: May 19, 2020
    Assignee: JW HOLDINGS CORPORATION
    Inventors: Young Ki Paik, Min Jung Lee
  • Immunotherapy against melanoma and other cancers
    Patent number: 10640547
    Abstract: A method of treating a patient who has melanoma includes administering to said patient a composition containing a population of activated T cells that selectively recognize cells in the patient that aberrantly express a peptide. A pharmaceutical composition contains activated T cells that selectively recognize cells in a patient that aberrantly express a peptide, and a pharmaceutically acceptable carrier, in which the T cells bind to the peptide in a complex with an MHC class I molecule, and the composition is for treating the patient who has melanoma. A method of treating a patient who has melanoma includes administering to said patient a composition comprising a peptide in the form of a pharmaceutically acceptable salt, thereby inducing a T-cell response to the melanoma.
    Type: Grant
    Filed: October 16, 2018
    Date of Patent: May 5, 2020
    Assignee: IMMATICS BIOTECHNOLOGIES GMBH
    Inventors: Annika Sonntag, Toni Weinschenk, Andrea Mahr, Oliver Schoor, Jens Fritsche, Harpreet Singh
  • Method for diagnosing cancer by detecting C-terminal segment of moesin in blood
    Patent number: 10641774
    Abstract: A method for assessing cancer comprising obtaining a biological sample of the subject, detecting a level of a C-terminal segment of moesin in the biological sample, wherein the level of the C-terminal segment of moesin detected in the biological sample of the subject is indicative of the subject developing or with an increased probability of developing cancer. The present application also provides a biomarker and a kit for assessing cancer, and uses of such biomarker. The present application also provides a method of treating cancer.
    Type: Grant
    Filed: April 22, 2015
    Date of Patent: May 5, 2020
    Assignee: SHANGHAI KEXIN BIOTECH CO., LTD.
    Inventors: Yue Zhang, Jun Bao
  • FKBP-L polypeptides and uses in angiogenesis-mediated disorders
    Patent number: 10577406
    Abstract: Disclosed are methods and compositions that employ FKBP-L polypeptides for modulating angiogenesis and/or tumor metastasis. The FKBP-L polypeptides may be used for the treatment of disorders mediated by angiogenesis such as cancer.
    Type: Grant
    Filed: May 31, 2016
    Date of Patent: March 3, 2020
    Assignee: ALMAC DISCOVERY LIMITED
    Inventors: Tracy Robson, Andrea Valentine, Martin Gerard O'Rourke, David Hirst
  • Peptides, combination of peptides and scaffolds for use in immunotherapeutic treatment of various cancers
    Patent number: 10576132
    Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
    Type: Grant
    Filed: May 17, 2018
    Date of Patent: March 3, 2020
    Assignee: Immatics Biotechnologies GmbH
    Inventors: Andrea Mahr, Toni Weinschenk, Oliver Schoor, Jens Fritsche, Harpreet Singh
  • Methods of identifying individuals at increased risk of lung cancer
    Patent number: 10570454
    Abstract: The invention provides the identification of oncogenic pathways activated in cytologically normal airway cells of individuals having or at risk of having lung disease, as well as specific gene expression patterns (biomarkers) associated with pathway activation. These biomarkers and pathways may provide prognostic and/or diagnostic indicators in lung disease, e.g., lung cancer. Additionally, these pathways and biomarkers may provide therapeutic targets for the treatment of lung disease, as well as markers for the assessment of treatment efficacy.
    Type: Grant
    Filed: September 29, 2014
    Date of Patent: February 25, 2020
    Assignees: Trustees of Boston University, University of Utah Research Foundation
    Inventors: Jerome S. Brody, Avrum Spira, Adam Gustafson, Andrea Bild
  • Peptides, combination of peptides and scaffolds for use in immunotherapeutic treatment of various cancers
    Patent number: 10525114
    Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
    Type: Grant
    Filed: May 17, 2018
    Date of Patent: January 7, 2020
    Assignee: Immatics Biotechnologies GmbH
    Inventors: Andrea Mahr, Toni Weinschenk, Oliver Schoor, Jens Fritsche, Harpreet Singh
  • Immunotherapy against melanoma and other cancers
    Patent number: 10519216
    Abstract: A method of treating a patient who has melanoma includes administering to said patient a composition containing a population of activated T cells that selectively recognize cells in the patient that aberrantly express a peptide. A pharmaceutical composition contains activated T cells that selectively recognize cells in a patient that aberrantly express a peptide, and a pharmaceutically acceptable carrier, in which the T cells bind to the peptide in a complex with an MHC class I molecule, and the composition is for treating the patient who has melanoma. A method of treating a patient who has melanoma includes administering to said patient a composition comprising a peptide in the form of a pharmaceutically acceptable salt, thereby inducing a T-cell response to the melanoma.
    Type: Grant
    Filed: July 5, 2019
    Date of Patent: December 31, 2019
    Assignee: Immatics Biotechnologies GmbH
    Inventors: Annika Sonntag, Toni Weinschenk, Andrea Mahr, Oliver Schoor, Jens Fritsche, Harpreet Singh
  • Yeast-based immunotherapy for Chordoma
    Patent number: 10507235
    Abstract: One embodiment of the invention relates to a method to treat chordoma in an individual who has chordoma. The method includes the step of administering to an individual who has chordoma, an immunotherapeutic composition comprising: (a) a yeast vehicle; and (b) a cancer antigen comprising at least one Brachyury antigen. Another embodiment of the invention relates to the use of an immunotherapeutic composition comprising a yeast vehicle and a cancer antigen comprising at least one Brachyury antigen to chordoma in an individual who has chordoma. Yet another embodiment of the invention relates to the use an immunotherapeutic composition comprising a yeast vehicle.
    Type: Grant
    Filed: March 19, 2014
    Date of Patent: December 17, 2019
    Assignees: GlobeImmune, Inc., The USA, as represented by the Secretary, Dept. of Health and Human Services
    Inventors: Timothy C. Rodell, David Apelian, Claudia Palena, Jeffrey Schlom
  • Diagnostic methods for liver disorders
    Patent number: 10495643
    Abstract: The present invention relates to methods of diagnosing a liver disorder in a patient, as well as methods of monitoring the progression of a liver disorder and/or methods of monitoring a treatment protocol of a therapeutic agent or a chemotherapeutic regimen. The invention also relates to assay methods used in connection with the diagnostic methods described herein.
    Type: Grant
    Filed: October 19, 2016
    Date of Patent: December 3, 2019
    Assignee: MESO SCALE TECHNOLOGIES, LLC.
    Inventors: Eli N. Glezer, Anu Mathew, Martin Stengelin, Mingyue Wang
  • Compositions and methods for detecting neoplasia
    Patent number: 10487363
    Abstract: Compositions and methods for the diagnosis, treatment, and prevention of neoplasia (e.g., colorectal cancer).
    Type: Grant
    Filed: January 23, 2014
    Date of Patent: November 26, 2019
    Assignee: The United States of America, as represented by the Secretary, Department of Health & Human Services
    Inventors: Soumen K. Manna, Kristopher W. Krausz, Frank J. Gonzalez
  • Peptides, combination of peptides as targets and for use in immunotherapy against gallbladder cancer and cholangiocarcinoma and other cancers
    Patent number: 10472407
    Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
    Type: Grant
    Filed: May 29, 2019
    Date of Patent: November 12, 2019
    Assignee: IMMATICS BIOTECHNOLOGIES GMBH
    Inventors: Andrea Mahr, Toni Weinschenk, Anita Wiebe, Oliver Schoor, Jens Fritsche, Harpreet Singh
  • Peptides, combination of peptides as targets and for use in immunotherapy against gallbladder cancer and cholangiocarcinoma and other cancers
    Patent number: 10464990
    Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
    Type: Grant
    Filed: May 23, 2017
    Date of Patent: November 5, 2019
    Assignee: IMMATICS BIOTECHNOLOGIES GMBH
    Inventors: Andrea Mahr, Toni Weinschenk, Anita Wiebe, Oliver Schoor, Jens Fritsche, Harpreet Singh
  • Immunotherapy against melanoma and other cancers
    Patent number: 10464991
    Abstract: A method of treating a patient who has melanoma includes administering to said patient a composition containing a population of activated T cells that selectively recognize cells in the patient that aberrantly express a peptide. A pharmaceutical composition contains activated T cells that selectively recognize cells in a patient that aberrantly express a peptide, and a pharmaceutically acceptable carrier, in which the T cells bind to the peptide in a complex with an MHC class I molecule, and the composition is for treating the patient who has melanoma. A method of treating a patient who has melanoma includes administering to said patient a composition comprising a peptide in the form of a pharmaceutically acceptable salt, thereby inducing a T-cell response to the melanoma.
    Type: Grant
    Filed: December 20, 2017
    Date of Patent: November 5, 2019
    Assignee: IMMATICS BIOTECHNOLOGIES GMBH
    Inventors: Annika Sonntag, Toni Weinschenk, Andrea Mahr, Oliver Schoor, Jens Fritsche, Harpreet Singh
  • Immunotherapy against melanoma and other cancers
    Patent number: 10435454
    Abstract: A method of treating a patient who has melanoma includes administering to said patient a composition containing a population of activated T cells that selectively recognize cells in the patient that aberrantly express a peptide. A pharmaceutical composition contains activated T cells that selectively recognize cells in a patient that aberrantly express a peptide, and a pharmaceutically acceptable carrier, in which the T cells bind to the peptide in a complex with an MHC class I molecule, and the composition is for treating the patient who has melanoma. A method of treating a patient who has melanoma includes administering to said patient a composition comprising a peptide in the form of a pharmaceutically acceptable salt, thereby inducing a T-cell response to the melanoma.
    Type: Grant
    Filed: October 19, 2018
    Date of Patent: October 8, 2019
    Assignee: IMMATICS BIOTECHNOLOGIES GMBH
    Inventors: Annika Sonntag, Toni Weinschenk, Andrea Mahr, Oliver Schoor, Jens Fritsche, Harpreet Singh
  • Immunotherapy against melanoma and other cancers
    Patent number: 10435455
    Abstract: A method of treating a patient who has melanoma includes administering to said patient a composition containing a population of activated T cells that selectively recognize cells in the patient that aberrantly express a peptide. A pharmaceutical composition contains activated T cells that selectively recognize cells in a patient that aberrantly express a peptide, and a pharmaceutically acceptable carrier, in which the T cells bind to the peptide in a complex with an MHC class I molecule, and the composition is for treating the patient who has melanoma. A method of treating a patient who has melanoma includes administering to said patient a composition comprising a peptide in the form of a pharmaceutically acceptable salt, thereby inducing a T-cell response to the melanoma.
    Type: Grant
    Filed: July 5, 2019
    Date of Patent: October 8, 2019
    Assignee: IMMATICS BIOTECHNOLOGIES GMBH
    Inventors: Annika Sonntag, Toni Weinschenk, Andrea Mahr, Oliver Schoor, Jens Fritsche, Harpreet Singh
  • Protection against stress-mediated damage from ionizing radiation
    Patent number: 10406206
    Abstract: The use and screening of modulators of apoptosis is disclosed. The modulators may be, for example, modulator of NF-?B activity. The modulators may be used, for example, in the treatment of NF-?B-mediated diseases, conditions, and injuries.
    Type: Grant
    Filed: January 24, 2017
    Date of Patent: September 10, 2019
    Assignee: The Cleveland Clinic Foundation
    Inventor: Andrei V. Gudkov
  • Antagonists for abdominal vasopressin V2 receptor and uses thereof
    Patent number: 10407504
    Abstract: Provided herein are antagonists or binding agents of an abnormal vasopressin receptor V2 (e.g., AbnV2), such as antibodies and antigen-binding portions thereof specific for the receptor, for identifying and targeting cancer cells expressing such abnormal vasopressin receptor V2. Additionally provided are methods of using said antagonists or binding agents, for example, to image cancer cells or in biological samples, or diagnose cancers, both in vivo and in vitro. The antagonists or binding agents may also be used for treating patients suffering from a cancer expressing the abnormal vasopressin receptor V2, such as small cell lung cancer (SCLC), breast cancer, or ovarian cancer.
    Type: Grant
    Filed: October 12, 2016
    Date of Patent: September 10, 2019
    Assignee: Woomera Therapeutics
    Inventors: William G. North, Roy H. L. Pang
  • Detection of histone modification in cell-free nucleosomes
    Patent number: 10408831
    Abstract: This invention relates to the diagnosis of disease conditions, such as cancer and autoimmune disease, by the analysis of cell-free nucleosomes in samples from individuals. Methods of the invention may include contacting cell-free nucleosomes from a biological fluid sample obtained from the individual with an antibody that binds specifically with a modified histone protein. Binding of the antibody to the nucleosomes is indicative that the individual has the disease condition.
    Type: Grant
    Filed: August 3, 2015
    Date of Patent: September 10, 2019
    Assignee: SINGAPORE VOLITION PTE. LIMITED
    Inventors: Lindsay Jane Bawden, Elisabeth Ann Bone, Alan Hastings Drummond, Lindsey Ann Needham
  • Immunotherapy against melanoma and other cancers
    Patent number: 10385110
    Abstract: A method of treating a patient who has melanoma includes administering to said patient a composition containing a population of activated T cells that selectively recognize cells in the patient that aberrantly express a peptide. A pharmaceutical composition contains activated T cells that selectively recognize cells in a patient that aberrantly express a peptide, and a pharmaceutically acceptable carrier, in which the T cells bind to the peptide in a complex with an MHC class I molecule, and the composition is for treating the patient who has melanoma. A method of treating a patient who has melanoma includes administering to said patient a composition comprising a peptide in the form of a pharmaceutically acceptable salt, thereby inducing a T-cell response to the melanoma.
    Type: Grant
    Filed: October 19, 2018
    Date of Patent: August 20, 2019
    Assignee: IMMATICS BIOTECHNOLOGIES GMBH
    Inventors: Annika Sonntag, Toni Weinschenk, Andrea Mahr, Oliver Schoor, Jens Fritsche, Harpreet Singh